654 related articles for article (PubMed ID: 24281250)
1. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
Ademi Z; Pasupathi K; Liew D
Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
Lanitis T; Kongnakorn T; Jacobson L; De Geer A
Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
[TBL] [Abstract][Full Text] [Related]
4. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
Cowper PA; Sheng S; Lopes RD; Anstrom KJ; Stafford JA; Davidson-Ray L; Al-Khatib SM; Ansell J; Dorian P; Husted S; McMurray JJV; Steg PG; Alexander JH; Wallentin L; Granger CB; Mark DB
JAMA Cardiol; 2017 May; 2(5):525-534. PubMed ID: 28355434
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Hernandez I; Smith KJ; Zhang Y
Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
[TBL] [Abstract][Full Text] [Related]
7. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.
Amin A; Stokes M; Wu N; Gatt E; Makenbaeva D; Wiederkehr D; Boulanger L
J Med Econ; 2013 Oct; 16(10):1193-202. PubMed ID: 23883416
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.
Li X; Tse VC; Lau WC; Cheung BM; Lip GY; Wong IC; Chan EW
PLoS One; 2016; 11(6):e0157129. PubMed ID: 27362421
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
Dorian P; Kongnakorn T; Phatak H; Rublee DA; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Lip GY
Eur Heart J; 2014 Jul; 35(28):1897-906. PubMed ID: 24513791
[TBL] [Abstract][Full Text] [Related]
13. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective.
Ademi Z; Pasupathi K; Liew D
Appl Health Econ Health Policy; 2017 Jun; 15(3):363-374. PubMed ID: 27699648
[TBL] [Abstract][Full Text] [Related]
16. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease.
Altawalbeh SM; Alshogran OY; Smith KJ
Value Health; 2018 Dec; 21(12):1365-1372. PubMed ID: 30502779
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan.
Kamae I; Hashimoto Y; Koretsune Y; Tanahashi N; Murata T; Phatak H; Liu LZ; Tang AC; Feng Wang P; Okumura K
Clin Ther; 2015 Dec; 37(12):2837-51. PubMed ID: 26608819
[TBL] [Abstract][Full Text] [Related]
18. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation.
Lee S; Mullin R; Blazawski J; Coleman CI
PLoS One; 2012; 7(10):e47473. PubMed ID: 23056642
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation.
Kamel H; Easton JD; Johnston SC; Kim AS
Neurology; 2012 Oct; 79(14):1428-34. PubMed ID: 22993279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]